Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The company is headquartered in North Billerica, Massachusetts and currently employs 1,193 full-time employees. The company went IPO on 2015-06-25. The firm's product categories include Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Others. The firm's Radiopharmaceutical Oncology products help healthcare professionals (HCPs) find, fight and follow cancer. The firm's Precision Diagnostic products assist HCPs to find and follow diseases. Its Strategic Partnerships include biomarkers and digital solutions in support of its partners’ therapeutic development, out-licensing agreements for non-core assets and optimization of its assets geographically. The firm's commercial products are used by cardiologists, internal medicine physicians, neurologists, nuclear medicine physicians, oncologists, radiologists, sonographers, technologists, and urologists working in a variety of clinical settings.
Quel est le ratio P/E de Lantheus Holdings Inc (LNTH) ?
Le ratio P/E de Lantheus Holdings Inc est de 21.117
Quelle est la performance du prix de l'action LNTH ?
Le prix actuel de LNTH est de $83.56, il a diminué de 0.65% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Lantheus Holdings Inc ?
Lantheus Holdings Inc appartient à l'industrie Health Care et le secteur est Health Care
Quel est la capitalisation boursière de Lantheus Holdings Inc ?
La capitalisation boursière actuelle de Lantheus Holdings Inc est de $5.4B
Est-ce que Lantheus Holdings Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 15 analystes ont établi des notations d'analystes pour Lantheus Holdings Inc, y compris 4 achat fort, 12 achat, 3 maintien, 0 vente et 4 vente forte